Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis healing:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally twice daily, but may be increased to 80 mg orally twice daily. Doses higher than 80 mg daily should be administered via intravenous infusion.
## Pediatric Dosing
* **Erosive esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **GERD (5 years and older):** 20 mg to 40 mg orally once daily for up to 8 weeks.
* Dosing in younger children is not well-established and should be individualized based on clinical response and physician discretion.
## Dose Adjustments
* **Hepatic Impairment:** For severe hepatic impairment, a maximum dose of 20 mg once daily is recommended.
* **Renal Impairment:** No dose adjustment is typically needed.
## Contraindications
* Known hypersensitivity to pantoprazole or any of its components, or to other substituted benzimidazoles.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Serious:** *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia (potentially symptomatic), fundic gland polyps.
## Key Drug Interactions
* **Drugs requiring gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, erlotinib, mycophenolate mofetil. Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Monitor closely.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs metabolized by this enzyme (e.g., clopidogrel, though clinical significance is debated).
## Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Consider monitoring serum magnesium levels with prolonged use (e.g., >1 year), especially in patients on other medications that may cause hypomagnesemia (e.g., diuretics).
* Monitor bone mineral density with long-term therapy, particularly in patients with risk factors for osteoporosis.
## Clinical Pearls
* Administer 30 minutes before a meal.
* For delayed-release tablets, instruct patients to swallow whole and not to chew or crush.
* Long-term use of PPIs is associated with increased risk of fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary to treat the condition.
***
*Always verify current prescribing information and consult with a healthcare professional for specific patient guidance.*
